The use of danaparoid to manage coagulopathy in a neurosurgical patient with heparin-induced thrombocytopenia type II and intracerebral haemorrhage.
This study presents a case of bifrontal intracerebral haemorrhage in a patient with heparin-induced thrombocytopenia type II (HIT II). HIT II was induced by treatment with low-molecular-weight heparin for recurrent deep vein thrombosis caused by essential thrombocytosis and accompanied by hepatic thromboembolism. This patient was treated with platelet substitution and neurosurgical haematoma evacuation. Anticoagulation with 2500 units danaparoid per day was sufficient for therapy of thrombosis and no rebleeding occurred.
Hertle
Daniel N
DN
Department of Neurosurgery, Ruprecht-Karls-Universität, Heidelberg, Germany. daniel.hertle@med.uni-heidelberg.de
Hähnel
Stefan
S
Richter
Götz M
GM
Unterberg
Andreas
A
Sakowitz
Oliver W
OW
Kiening
Karl L
KL
D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects*; D001778:Blood Coagulation Disorders / Q000188:drug therapy; D002543:Cerebral Hemorrhage / Q000139:chemically induced / Q000188:drug therapy*; D002809:Chondroitin Sulfates / Q000008:administration & dosage*; D019457:Chromosome Breakage; D025063:Chromosome Disorders / Q000139:chemically induced / Q000188:drug therapy; D003871:Dermatan Sulfate / Q000008:administration & dosage*; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D013921:Thrombocytopenia / Q000139:chemically induced / Q000151:congenital / Q000188:drug therapy; D016896:Treatment Outcome
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006495:Heparin, Low-Molecular-Weight; D006497:Heparan Sulfate; C035838:danaparoid